Table 1.

Characteristics of the eligible studies.

Study ID	Study	Sample size	Treatment	Age	Male (%)	Diagnosis level	Proportion of patients with severe EE at baseline (%)	4-Week healing rate		8-Week healing rate
								Event	Total	Event	Total
1	Sontag et al., 199240	91	Omeprazole 40 mg qd	NR	NR	HD II–IV	About 50	40	91	66	91
1	Sontag et al., 199240	93	Omeprazole 20 mg qd	NR	NR	HD II–IV		36	93	68	93
1	Sontag et al., 199240	46	Placebo	NR	NR	HD II–IV		3	46	7	46
2	Hatlebakk et al., 199341	116	Lansoprazole 30 mg qd	54.3	66.4	1–2 a	0	71	113	95	112
2	Hatlebakk et al., 199341	113	Omeprazole 20 mg qd	55.4	65.5	1–2 a		73	112	96	111
3	Corinaldesi et al., 199542	121	Omeprazole 20 mg qd	52	62	SM II–III	18.3	83	105	96	105
3	Corinaldesi et al., 199542	120	Pantoprazole 40 mg qd	50	65	SM II–III		81	103	97	103
4	Mössner et al., 199543	95	Omeprazole 20 mg qd	55	69	SM II–III	20.3	67	86	81	86
4	Mössner et al., 199543	191	Pantoprazole 40 mg qd	53	70	SM II–III		126	170	153	170
5	Castell et al., 199644	422	Lansoprazole 30 mg qd	48.6	68.4	II–IV a	34.8	335	421	367	421
5	Castell et al., 199644	431	Omeprazole 20 mg qd	47.5	60.3	II–IV a		343	431	375	431
5	Castell et al., 199644	213	Placebo	47.6	66.7	II–IV a		62	213	68	213
6	Mee and Rowley, 199645	300	Lansoprazole 30 mg qd	53.4	66.0	SM 1–4	16.6	186	300	226	300
6	Mee and Rowley, 199645	304	Omeprazole 20 mg qd	52.4	67.1	SM 1–4		172	304	216	304
7	Earnest et al., 199846	71	Lansoprazole 30 mg qd	NR	NR	II–IV a	NR	52	71	62	71
7	Earnest et al., 199846	79	Lansoprazole 60 mg qd	NR	NR	II–IV a		60	79	70	79
7	Earnest et al., 199846	66	Placebo	NR	NR	II–IV a		20	66	31	66
8	Dekkers et al., 199947	102	Omeprazole 20 mg qd	52 ± 15.56	71.6	HD II–IV	56.9	83	102	96	102
8	Dekkers et al., 199947	100	Rabeprazole 20 mg qd	54 ± 15.70	53	HD II–IV		81	100	92	100
9	Vcev et al., 199948	60	Omeprazole 20 mg qd	NR	NR	SM 1–2	0	43	60	56	60
9	Vcev et al., 199948	60	Pantoprazole 40 mg qd	NR	NR	SM 1–2		46	60	57	60
10	Delchier et al., 200049	103	Omeprazole 20 mg qd	53 ± 15.1	39	HD II–IV	Median grade: 3.0; mean grade: 2.6	94	103	97	103
10	Delchier et al., 200049	103	Rabeprazole 10 mg bid	52 ± 14.3	30	HD II–IV		88	103	94	103
10	Delchier et al., 200049	104	Rabeprazole 20 mg qd	55 ± 15.7	45	HD II–IV		92	104	95	104
11	Kahrilas et al., 200050	654	Esomeprazole 40 mg qd	44.8 ± 13.0	58.7	LA A–D	26.7	496	654	615	654
11	Kahrilas et al., 200050	650	Omeprazole 20 mg qd	46.5 ± 13.5	61.4	LA A–D		421	650	565	650
12	Richter and Bochenek, 200051	173	Pantoprazole 40 mg qd	49.3 ± 13.6	69.9	HD II–IV	44.5	125	173	152	173
12	Richter and Bochenek, 200051	82	Placebo	48.3 ± 14.0	64.6	HD II–IV		11	82	27	82
13	Dupas and Houcke, 200152	235	Lansoprazole 30 mg qd	55.0 ± 14.7	75	SM II–III	17	189	235	201	235
13	Dupas and Houcke, 200152	226	Pantoprazole 40 mg qd	53.0 ± 14.5	73	SM II–III		184	226	203	226
14	Richter et al., 200153	1216	Esomeprazole 40 mg qd	NR	59.4	LA I–IV	26.4	993	1216	1139	1216
14	Richter et al., 200153	1209	Omeprazole 20 mg qd	NR	62.9	LA I–IV		831	1209	1018	1209
15	Castell et al., 200254	2624	Esomeprazole 40 mg qd	47.0 ± 13.0	57.4	LA A–D	24.6	2083	2624	2430	2624
15	Castell et al., 200254	2617	Lansoprazole 30 mg qd	47.4 ± 13.1	57.3	LA A–D		1965	2617	2324	2617
16	Howden et al., 200255	141	Esomeprazole 40 mg qd	46 ± 13	76	II–IV a	39.4	108	138	123	138
16	Howden et al., 200255	143	Lansoprazole 30 mg qd	47 ± 12	82	II–IV a		107	139	127	139
17	Gillessen et al., 200456	114	Esomeprazole 40 mg qd	54 ± 14	50	LA B–C	16.5	68	103	92	103
17	Gillessen et al., 200456	113	Pantoprazole 40 mg qd	53 ± 15	57	LA B–C		55	94	94	94
18	Fennerty et al., 200557	498	Esomeprazole 40 mg qd	47.3 ± 13.2	65.7	LA C–D	100	292	498	410	498
18	Fennerty et al., 200557	501	Lansoprazole 30 mg qd	47.1 ± 12.9	66.5	LA C–D		247	501	388	501
19	Labenz et al., 200558	1562	Esomeprazole 40 mg qd	50.6 ± 14.0	62	LA I–IV	24.4	1265	1562	1492	1562
19	Labenz et al., 200558	1589	Pantoprazole 40 mg qd	50.5 ± 13.8	63.7	LA I–IV		1184	1589	1462	1589
20	Pace et al., 200559	277	Omeprazole 20 mg qd	47.1 ± 14.9	67.7	SM I–III	29.7	213	237	231	237
20	Pace et al., 200559	283	Rabeprazole 20 mg qd	47.7 ± 14.2	68.6	SM I–III		212	233	228	233
21	Schmitt et al., 200661	576	Esomeprazole 40 mg qd	47.1 ± 13.3	60.1	LA A–D	26.6	393	576	501	576
21	Schmitt et al., 200661	572	Omeprazole 20 mg qd	46.2 ± 13.6	58.6	LA A–D		379	572	491	572
22	Vcev et al., 200662	90	Esomeprazole 40 mg qd	51.2 ± 14.5	63.3	LA I–III	31.4	70	90	83	90
22	Vcev et al., 200662	90	Pantoprazole 40 mg qd	49.4 ± 13.9	65.6	LA I–III		65	90	82	90
23	Bardhan et al., 200763	293	Esomeprazole 40 mg qd	54 ± 14	53	LA A–D	34.6	202	293	243	293
23	Bardhan et al., 200763	288	Pantoprazole 40 mg qd	53 ± 14	49	LA A–D		199	288	248	288
24	Zheng, 200964	68	Esomeprazole 40 mg qd	57.4 ± 12.8	48.5	LA A–D	32.1	NR	NR	65	68
24	Zheng, 200964	69	Lansoprazole 30 mg qd	58.1 ± 13.0	50.7	LA A–D		NR	NR	62	69
24	Zheng, 200964	68	Omeprazole 20 mg qd	57.9 ± 14.1	48.5	LA A–D		NR	NR	60	68
24	Zheng, 200964	69	Pantoprazole 40 mg qd	57.8 ± 13.2	49.3	LA A–D		NR	NR	63	69
25	Ashida et al., 201530	140	Lansoprazole 30 mg qd	55.8 ± 13.92	70.7	LA A–D	33.6	123	132	126	132
25	Ashida et al., 201530	154	Vonoprazan 20 mg qd	58.3 ± 13.86	74.7	LA A–D		136	144	139	144
25	Ashida et al., 201530	146	Vonoprazan 40 mg qd	57.6 ± 12.83	78.1	LA A–D		130	134	130	134
26	Ashida et al., 201629	202	Lansoprazole 30 mg qd	57.4 ± 13.2	76.2	LA A–D	36.2	184	199	190	199
26	Ashida et al., 201629	207	Vonoprazan 20 mg qd	58.3 ± 13.8	66.2	LA A–D		198	205	203	205
27	Xue et al., 201665	105	Esomeprazole 40 mg qd	47.8 ± 11.65	68.6	LA A–D	10.8	75	105	89	105
27	Xue et al., 201665	107	Ilaprazole 10 mg qd	48.9 ± 12.63	70.1	LA A–D		87	107	95	107
28	Xue et al., 201866	215	Esomeprazole 40 mg qd	47.5 ± 12.32	70.7	LA A–D	6.1	167	215	178	215
28	Xue et al., 201866	322	Ilaprazole 10 mg qd	48.2 ± 11.96	72.0	LA A–D		245	322	269	322
29	Xiao et al., 202067	237	Lansoprazole 30 mg qd	53.8 ± 12.53	75.5	LA A–D	29.9	192	230	210	230
29	Xiao et al., 202067	244	Vonoprazan 20 mg qd	54.1 ± 13.16	72.1	LA A–D		203	238	220	238
30	Lee et al., 201931	99	Esomeprazole 40 mg qd	50.4 (21.0–75.0)	53.5	LA A–D	4.3	87	99	92	99
30	Lee et al., 201931	102	Tegoprazan 100 mg qd	52.8 (20.0–74.0)	64.7	LA A–D		92	102	97	102
30	Lee et al., 201931	99	Tegoprazan 50 mg qd	52.7 (21.0–74.0)	62.6	LA A–D		87	99	95	99
31	Chen et al., 202223	119	Keverprazan 20 mg qd	49.7 ± 12.1	83.2	LA A–D	20.6	98	119	114	119
31	Chen et al., 202223	119	Lansoprazole 30 mg qd	48.8 ± 12.3	76.5	LA A–D		97	119	107	119
32	Laine et al., 202368	510	Lansoprazole 30 mg qd	51.7 ± 14.1	45.7	LA A–D	34.3	NR	NR	431	510
32	Laine et al., 202368	514	Vonoprazan 20 mg qd	51.0 ± 13.4	50.2	LA A–D		NR	NR	478	514
33	Lee et al., 202269	115	Esomeprazole 40 mg qd	55.05 ± 12.89	64.3	LA A–D	6.9	92	104	110	111
33	Lee et al., 202269	116	Fexuprazan 40 mg qd	53.70 ± 12.44	67.2	LA A–D		93	103	106	107
34	Lightdale et al., 200660	588	Omeprazole 20 mg qd	45.3 ± 13.0	63.9	LA A–D	26.2	NR	NR	484	588

^aThese articles do not specify the endoscopic grading scale.

HD, Hetzel–Dent; LA, Los Angeles; SM, Savary–Miller; NR, not report.